External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different

• Κύριοι συγγραφείς: Andrew Dodson (Συγγραφέας), Suzanne Parry (Συγγραφέας), Birgit Lissenberg‐Witte (Συγγραφέας), Alex Haragan (Συγγραφέας), David Allen (Συγγραφέας), Anthony O'Grady (Συγγραφέας), Emma McClean (Συγγραφέας), Jamie Hughes (Συγγραφέας), Keith Miller (Συγγραφέας), Erik Thunnissen (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Wiley, 2020-04-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Abstract PD‐L1 inhibitors are part of first line treatment options for patients with advanced non‐small cell lung cancer. PD‐L1 immunohistochemistry (IHC) assays act as either a companion or a complementary diagnostic. The purpose of this study is to describe the experience of external quality assur...